Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 8/20 | 0.44 |
| ▸ | KIT | P10721 | 4/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | DTYMK | P23919 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22978459 | 0.90 | CSF1R (0.35) | CSF1RKITPDGFRAACHEDDB1 | |
| SCHEMBL22988846 | 0.79 | CSF1R (0.45) | CSF1RKITPDGFRA | |
| SCHEMBL22978450 | 0.76 | ELANE (0.39) | DTYMKELANEL3MBTL1 | |
| SCHEMBL22978451 | 0.76 | L3MBTL1 (0.41) | DTYMKELANEL3MBTL1PDE10A | |
| SCHEMBL22988876 | 0.72 | CSF1R (0.46) | CSF1RKITPDGFRA | |
| SCHEMBL22988865 | 0.71 | CSF1R (0.45) | CSF1RKITPDGFRA | |
| SCHEMBL22988862 | 0.70 | CSF1R (0.44) | CSF1RKITPDGFRA | |
| SCHEMBL22978560 | 0.69 | GPR84 (0.41) | CSF1RKITPDGFRA | |
| SCHEMBL4505573 | 0.69 | L3MBTL1 (0.39) | DDB1CRBNDTYMKELANEL3MBTL1 | |
| SCHEMBL4569771 | 0.69 | L3MBTL1 (0.50) | DTYMKELANEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018233526-A9 | CSF1R INHIBITOR, AND MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-20160340361-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340361-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | JAK2, JAK3, PAK3 | CSF1R 1210/4885KIT 360/4885PDGFRA 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.